METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS
This application describes the use of the compound or a salt thereof, either alone or in combination with other therapeutically active agents, for the treatment of particular cancers, including any solid or hematological cancer in which AXL or c-Met is over-expressed.
1 .- 27 . (canceled)
28 . A method of treating non-small cell lung cancer in a subject, the method comprising administering to the subject a combination of (i) erlotinib or gefitinib, and (ii) a compound having the structure of:
or a pharmaceutically acceptable salt thereof, wherein the non-small cell lung cancer is resistant or insensitive to treatment with one or more EGFR inhibitors.
29 . The method of claim 28 , wherein the one or more EGFR inhibitors are erlotinib and/or gefitinib.
30 . The method of claim 28 , wherein the one or more EGFR inhibitors is erlotinib.
31 . The method of claim 28 , wherein the one or more EGFR inhibitors is gefitinib.
32 . The method of claim 28 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered to the subject from one to four times daily.
33 . The method of claim 32 , wherein the compound, or a pharmaceutically acceptable salt thereof, is administered to the subject in an amount from about 10 mg/kg to about 55 mg/kg.